299 related articles for article (PubMed ID: 27484667)
21. Kidney volume and function in autosomal dominant polycystic kidney disease.
Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
[TBL] [Abstract][Full Text] [Related]
22. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
23. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.
Brosnahan GM; You Z; Wang W; Gitomer BY; Chonchol M
Curr Hypertens Rev; 2021; 17(3):228-237. PubMed ID: 32807060
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.
Chen D; Ma Y; Wang X; Yu S; Li L; Dai B; Mao Z; Sun L; Xu C; Rong S; Tang M; Zhao H; Liu H; Serra AL; Graf N; Liu S; Wüthrich RP; Mei C
PLoS One; 2014; 9(3):e92232. PubMed ID: 24651850
[TBL] [Abstract][Full Text] [Related]
25. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
[TBL] [Abstract][Full Text] [Related]
26. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
27. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
Chapman AB
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1197-204. PubMed ID: 18579674
[TBL] [Abstract][Full Text] [Related]
28. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT; Torres VE
Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
[TBL] [Abstract][Full Text] [Related]
30. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
[TBL] [Abstract][Full Text] [Related]
31. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
32. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.
Yu ASL; Shen C; Landsittel DP; Grantham JJ; Cook LT; Torres VE; Chapman AB; Bae KT; Mrug M; Harris PC; Rahbari-Oskoui FF; Shi T; Bennett WM;
Kidney Int; 2019 May; 95(5):1253-1261. PubMed ID: 30922668
[TBL] [Abstract][Full Text] [Related]
33. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
[TBL] [Abstract][Full Text] [Related]
34. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
[TBL] [Abstract][Full Text] [Related]
35. Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.
Seliger SL; Watnick T; Althouse AD; Perrone RD; Abebe KZ; Hallows KR; Miskulin DC; Bae KT
Kidney360; 2020 Dec; 1(12):1363-1372. PubMed ID: 33768205
[TBL] [Abstract][Full Text] [Related]
36. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Srivastava A; Irazabal MV; Abebe KZ; Harris PC; Landsittel DP;
J Am Soc Nephrol; 2020 Jul; 31(7):1640-1651. PubMed ID: 32487558
[TBL] [Abstract][Full Text] [Related]
37. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.
Nowak KL; You Z; Gitomer B; Brosnahan G; Torres VE; Chapman AB; Perrone RD; Steinman TI; Abebe KZ; Rahbari-Oskoui FF; Yu ASL; Harris PC; Bae KT; Hogan M; Miskulin D; Chonchol M
J Am Soc Nephrol; 2018 Feb; 29(2):571-578. PubMed ID: 29118087
[TBL] [Abstract][Full Text] [Related]
38. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
[TBL] [Abstract][Full Text] [Related]
39. Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients.
Chen H; Watnick T; Hong SN; Daly B; Li Y; Seliger SL
BMC Nephrol; 2019 Oct; 20(1):386. PubMed ID: 31653199
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
